Investasi
Fitur
BiayaKeamanan
Akademi
Lainnya
Pluang+

Bandingkan Harga & Kinerja Organon Pharma Indonesia Tbk. (SCPI) vs Solusi Bangun Indonesia Tbk. (SMCB)

Organon Pharma Indonesia Tbk.Trading
Solusi Bangun Indonesia Tbk.Trading

Kinerja harga (24 Jam Terakhir)

Statistik utama

Perbedaan Organon Pharma Indonesia Tbk. dan Solusi Bangun Indonesia Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Solusi Bangun Indonesia Tbk. diperdagangkan di Rp775 (kapitalisasi pasar 6,99 T). Perbedaan utamanya: Solusi Bangun Indonesia Tbk. jauh lebih besar — sekitar 67× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.

SCPISMCB
Kapitalisasi Pasar
104,4 M6,99 T

Perbandingan imbal hasil

Imbal hasil berjalan pada periode standar

Berita terkini

Berita terbaru kedua aset

SCPI
Lihat detail
SMCB
Lihat detail

Tentang Organon Pharma Indonesia Tbk.

PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.

Selengkapnya di halaman SCPI

Tentang Solusi Bangun Indonesia Tbk.

PT Holcim Indonesia Tbk (the Company) was originally a joint venture between a subsidiary of Kaiser Cement and Gypsum Corp. and PT Semen Gresik. Founded in 1971, the company owns a factory in Narogong, West Java, with an annual capacity of 3 million tons. The Company changed its foreign capital investment status (PMA) to domestic capital investment (PMDN) based on the approval from Chairman of Capital Investment Coordinating Board No. 17/V/1988 dated November 19, 1988. Effective January 1, 2006, the Company changed its name from PT Semen Cibinong Tbk. to PT Holcim Indonesia Tbk.

Selengkapnya di halaman SMCB